Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2003

View Archived Issues

High doses of interferon beta-1b effective in early relapsing-remitting MS

Atorvastatin reduces cardiovascular events in hypertensive patients with average cholesterol levels

New data on urokinase in intracerebral hematoma

Protective effects against malaria reported for a novel primaquine analogue

Antitumor acridine derivatives prepared and tested at Servier

Three series of IBAT inhibitors identified by AstraZeneca scientists

Novel glucose-lowering agents in Sankyo research pipeline

GSK-3beta or dual GSK-3beta/CDK5 inhibitors for use in AD and other disorders

BMS researchers present new CRF antagonists with utility in anxiety, depression, etc.

Triapine evaluated clinically in combination with cytarabine for leukemia

Macrocyclic modulators of c-fos expression and their use in cancer therapy

Regenecor established to acquire PPL subsidiary

Genmab reviews developments in 2002

Gastrointestinal effects of the kappa opioid receptor agonist asimadoline

A humanized anti-EGFR monoclonal antibody reported safe in advanced epithelial cancer

Potential use of mozavaptan plus furosemide for treating edema and hyponatremia

Activa Therapy receives humanitarian device exemption for dystonia

Ortho-McNeil to acquire Axert marketing rights

Medarex and Pfizer form antibody development partnership

Praecis submits IND to begin phase I trial of PPI-2458 in NHL

GlaxoSmithKline files IND for topotecan TCS

FDA approves Vigamox

Achillion and Phytobiotech to discover drugs for infectious disease

Merger of Pfizer and Pharmacia expected to result in major synergies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.